On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...

AstraZeneca PLC AZN shares rallied 2.39% to £110.52 Tuesday, on what proved to be an all-around great trading session for the ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

AstraZeneca PLC ADR closed 22.49% short of its 52-week high of $87.68, which the company reached on August 30th.

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

AstraZeneca's bold vision for a cutting-edge vaccine facility in Speke is caught in a web of delays, leaving the biotech ...

Trinasolar, a global leader in smart PV and energy storage, has partnered with Smart Commercial Solar to deliver an advanced ...

AstraZeneca (AZN) has overhauled its local management in China in a bid to move on from recent scandals and revive sales after the arrest of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

President Trump rescinded an executive order that prompted the creation of three Medicare drug-pricing experiments ...

UK’s former vaccine tsar says immunocompromised people were ‘de-prioritised’ in a ‘two-tier’ therapeutic rollout strategy ...

Tempus AI is projected to achieve 30% YoY top line growth in Q4 2024 as presented in its preliminary results. Click here to ...